Equities analysts predict that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will post sales of $130,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Idera Pharmaceuticals’ earnings, with the highest sales estimate coming in at $150,000.00 and the lowest estimate coming in at $100,000.00. Idera Pharmaceuticals posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is scheduled to report its next quarterly earnings results on Wednesday, May 8th.
On average, analysts expect that Idera Pharmaceuticals will report full year sales of $490,000.00 for the current financial year, with estimates ranging from $400,000.00 to $580,000.00. For the next fiscal year, analysts expect that the business will report sales of $6.79 million, with estimates ranging from $420,000.00 to $13.15 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Idera Pharmaceuticals.
Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.12 million.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter valued at $33,000. Assenagon Asset Management S.A. acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter valued at $1,153,000. Candriam Luxembourg S.C.A. lifted its position in shares of Idera Pharmaceuticals by 48.7% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 290,000 shares of the biotechnology company’s stock valued at $803,000 after acquiring an additional 95,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Idera Pharmaceuticals during the 3rd quarter valued at $200,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Idera Pharmaceuticals during the 3rd quarter valued at $132,000. 44.71% of the stock is owned by hedge funds and other institutional investors.
IDRA stock traded down $0.04 on Tuesday, reaching $2.39. The company’s stock had a trading volume of 158,287 shares, compared to its average volume of 254,546. Idera Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $17.12. The firm has a market capitalization of $66.01 million, a price-to-earnings ratio of -1.05 and a beta of 2.55.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.